Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years

Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years

Abstract Introduction Upadacitinib (UPA) is a Janus kinase inhibitor that has demonstrated efficacy in moderate-to-severe rheumatoid arthritis (RA) with an acceptable safety profile. We investigated laboratory parameter changes in UPA RA clinical trials. Methods Pooled data from six randomized trial...

Full description

Bibliographic Details
Main Authors: Christina Charles-Schoeman, Jon T. Giles, Nancy E. Lane, Ernest Choy, Daniel E. Furst, Jiří Vencovský, Anthony G. Wilson, Gerd R. Burmester, Derek Coombs, Sara K. Penn, Nasser Khan, Jillian B. Yee, Kassim Rahawi, Iain B. McInnes
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-01-01
Series:Rheumatology and Therapy
Subjects:
JAK inhibitor
Laboratory parameters
Rheumatoid arthritis
Upadacitinib
Online Access:https://doi.org/10.1007/s40744-023-00624-3

Internet

https://doi.org/10.1007/s40744-023-00624-3

Similar Items